CMV Serostatus

D+R-
- Offer prophylaxis to people receiving kidney and liver transplants for at least 3 months following transplantation
- Consider prophylaxis for people receiving heart, lung, intestinal or pancreas transplants for at least 3 months following transplantation

D+R+
- Received T-lymphocyte depletion therapy with Antithymocyte globulin (ATG) or Alemtuzumab (Campath®)
- Offer monitoring of CMV viral load for at least 3 months to guide pre-emptive therapy

D-R+
- YES
- NO
- Treatment for Acute rejection

D-R-
- Prophylaxis not recommended†
- Routine CMV monitoring not recommended
- CMV testing based on clinical signs and/or symptoms

† Be aware that some recipients who are seronegative for CMV (D-/R-) may require Valganciclovir or Valaciclovir prophylaxis for prevention of other Herpes virus infections